Product Description
Gabapentin enacarbil is used to treat moderate-to-severe primary Restless Legs Syndrome (RLS). RLS is a neurologic disorder that makes the legs feel uncomfortable. This results in an irresistible feeling of wanting to move your legs to make them comfortable. (Sourced from: https://www.mayoclinic.org/drugs-supplements/gabapentin-enacarbil-oral-route/description/drg-20122596)
Mechanisms of Action: Calcium Channel Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Egypt | Japan | United States
Approved Indications: Neuralgia | Neuralgia, Postherpetic | Restless Legs Syndrome
Known Adverse Events: Dizziness | Headache
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|